Sector News

With inversion pushback mounting, Akorn eyes bid for UCB subsidiary

September 12, 2014
Life sciences
The threat of action from lawmakers may have put a damper on pharma’s tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois’ Akorn, which is reportedly looking into a bid for Belgian pharma UCB’s U.S. subsidiary.
 
The Lake Forest pharma is one of a small number of companies exploring a buyout of New Jersey-based Kremers Urban Pharmaceuticals, sources tell Reuters. Back in August, the news service reported that UCB was interested in hiving off the business in a slim-down effort, another pharma trend that’s currently in vogue.
 
With a pickup of Kremers, Akorn could shift its tax domicile to Europe–cutting down its relatively high rate, Reuters says. Akorn, with a market cap of $3.8 billion, will pay an estimated 37% this fiscal year, compared with the industry average of 23%.
 
Kremers, which makes specialty generics products, would also build up Akorn’s own specialty lineup, which includes ophthalmic and injectable offerings. But there may be other suitors on hand as well, with Impax Laboratories, Lupin and Lannett among those for whom Kremers could make an attractive target.
 
U.S. political pressure on companies eyeing tax-fueled deals has been mounting, with Treasury Secretary Jack Lew announcing on Monday that his department planned to make a decision “in the very near future” about how to stem the inversion tide. Industry-watchers have said the threat of action from lawmakers could be holding some transactions up–like Hospira’s reported deal for the nutrition unit of French company Danone, which recently stalled.
 
But others–including pharma giant Pfizer–are pressing full steam ahead to snag a tax break. Earlier this week, company execs told Bernstein Research analyst Tim Anderson that without one, Pfizer can’t properly compete with overseas companies–meaning it’ll be on the lookout whether or not it can get former target AstraZeneca ($AZN) to come to the table.
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”